<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11860403</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1440</article-id><article-id pub-id-type="other">EPV0815</article-id><article-id pub-id-type="pii">S0924933824014408</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Intranasal esketamine efficacy as a treatment for treatment-resistant depression, case series</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Delgado Marmisa</surname><given-names>C.</given-names></name><xref rid="aff3172" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>&#x000c1;lvarez Correa</surname><given-names>I.</given-names></name><xref rid="aff3172" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vizca&#x000ed;no Herrezuelo</surname><given-names>H.</given-names></name><xref rid="aff3172" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Eg&#x000fc;en Recuero</surname><given-names>L.</given-names></name><xref rid="aff3172" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Garrido Dobrito</surname><given-names>E.</given-names></name><xref rid="aff3172" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gayubo Moreo</surname><given-names>L.</given-names></name><xref rid="aff3172" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sanz-Aranguez</surname><given-names>B.</given-names></name><xref rid="aff3172" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Delgado Tellez</surname><given-names>L.</given-names></name><xref rid="aff3173" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Caballero Mart&#x000ed;nez</surname><given-names>L.</given-names></name><xref rid="aff3172" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>De Arce Cord&#x000f3;n</surname><given-names>R.</given-names></name><xref rid="aff3172" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jim&#x000e9;nez-Fern&#x000e1;ndez</surname><given-names>B.</given-names></name><xref rid="aff3174" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cor1290" ref-type="corresp">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff3172"><sup>1</sup>Psychiatry</aff><aff id="aff3173"><sup>2</sup>Pharmacology, <institution>Hospital Universitario Puerta de Hierro Majadahonda</institution>, <city>Majadahonda</city></aff><aff id="aff3174"><sup>3</sup>Department of Psychiatry, <institution>Hospital Universitari Germans Trias i Pujol</institution>, <city>Barcelona</city>, <country>Spain</country></aff><author-notes><corresp id="cor1290"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1415">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S692</fpage><lpage>S692</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824014408a.pdf"/><abstract><sec id="sec7754"><title>Introduction</title><p>Intranasal esketamine has been approved as a treatment for patients with treatment-resistant depression. We analyzed the results of its efficacy in 15 patients.</p></sec><sec id="sec7755"><title>Objectives</title><p>To evaluate the efficacy of intranasal Esketamine as a treatment in patients with treatment-resistant depression</p></sec><sec id="sec7756"><title>Methods</title><p>Case series</p></sec><sec id="sec7757"><title>Results</title><p>For the last 8 months, since the treatment with intranasal esketamine was approved for resistant depression, we have treated 14 patients with this drug. Through this process, we followed a standardized method consisting in the following steps:</p><p>On the first esketamine session (DAY 1) the patient has to fill a CGI and a MADRS scale.</p><p>On the second esketamine session (DAY 7) the patient has to fill a CGI, a MADRS scale, a form about the level of satisfaction with the drug and a last form in which they can include the secondary effects.</p><p>On week 6 since the start of the treatment, the patient has to fill again a CGI, a MADRS scale, a form about the level of satisfaction with the drug and a last form in which they can include the secondary effects.</p><p>In the 6th month since the start of the treatment, the patient has to fill again a CGI, a MADRS scale, a form about the level of satisfaction with the drug and a last form in which they can include the secondary effects they have perceived.</p><p>We analyzed and compared all of the previous data and obtained the following results:</p><p>At day 7: 64% of the patients had a response in the form of improvement, of which 66% were feeling &#x0201c;slightly better&#x0201d; and 33% were feeling &#x0201c;better&#x0201d;.</p><p>At week 6: 71% of the patients had a response in the form of improvement, of which 50% were feeling &#x0201c;slightly better&#x0201d; and the other 50% were feeling &#x0201c;better&#x0201d;.</p><p>At month 6: only 28% of the patients completed the treatment; of which 100% had a response in the form of improvement: 50% were feeling &#x0201c;slightly better&#x0201d;, 25% were feeling &#x0201c;better&#x0201d; and 25% were feeling &#x0201c;far better&#x0201d;.</p></sec><sec id="sec7758"><title>Conclusions</title><p>Although our data suggests that intranasal esketamine has been effective in short term depressive symptoms, we have yet no information about its medium and long-term efficacy or secondary effects. Nevertheless, other potential factors should be evaluated as they could affect the results in the long-term such as the difficulty in maintaining the treatment for more than 6 weeks.</p><p>In addition, the patients who experienced the most improvement according to our data were patients with a TAB diagnosis, so this could be an interesting research focus.</p></sec><sec id="sec7759"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>